Table 2.
Prescribed lipid-lowering treatment at latest visit.
| n | ||
|---|---|---|
| Statin treatment, n (%) | 371 | 370 (99.7) |
| Any atorvastatin dose | 210 (56.6) | |
| Atorvastatin 5 mg | 2 (0.5) | |
| Atorvastatin 10 mg | 58 (15.6) | |
| Atorvastatin 20 mg | 66 (17.8) | |
| Atorvastatin 40 mg | 70 (18.9) | |
| Atorvastatin 80 mg | 14 (3.8) | |
| Any rosuvastatin dose | 126 (34.0) | |
| Rosuvastatin 5 mg | 15 (4.0) | |
| Rosuvastatin 10 mg | 37 (10.0) | |
| Rosuvastatin 20 mg | 44 (11.9) | |
| Rosuvastatin 40 mg | 30 (8.1) | |
| Any simvastatin dose | 34 (9.2) | |
| Simvastatin 10 mg | 4 (1.1) | |
| Simvastatin 20 mg | 13 (3.5) | |
| Simvastatin 40 mg | 13 (3.5) | |
| Simvastatin 80 mg | 4 (1.1) | |
| Ezitimibe treatment, n (%) | 371 | 117 (31.5) |
| PCSK9-inhibitor, n (%) | 371 | 1 (0.5) |
PCSK9, proprotein convertase subtilisin/kexin type 9.